ClinicalTrials.gg
Not yet recruitingNCT07739537PATHS-T2DUpdated Aug 31, 2026

PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

A Phase 4 interventional study of Orforglipron in Diabete Type 2 and Pharmacogenomic Drug Interaction, sponsored by Massachusetts General Hospital. Not yet recruiting. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Other

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Planned enrollment
13th of 15
100 · median 546
Started
2026
with 2 others
Phase 4
Only one
of the 15
Registered
15th of 15
by date
Lead sponsor
1 of 15
Massachusetts General Hospital

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 4, and was the 15th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This research study aims to learn about how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for long-term weight management. In longer studies, it has helped people lose weight and improve blood sugar, blood pressure, and cholesterol. By taking part, participants will receive detailed metabolic testing and may receive study results with additional information about their blood sugar and metabolic health.

Read the detailed description

This clinical research study uses a recall-by-genotype strategy to characterize physiologic responses associated with specific genetic pathways and to determine physiological responses and changes under orforglipron challenge.

This study will enroll approximately 100 adults aged 18-79 years who have previously agreed to be recontacted for future studies through the MGB biobank. The target sample size may be adjusted depending on funding availability and to power pharmacologic challenges. The study population will consist of four groups of high genetic risk for glycemic/insulinemic associations based on three pPS, along with controls selected from the interquartile range (IQR) across all pPS to provide a mechanism-agnostic comparator. Blood glucose, insulin, and incretin hormone levels will be measured during a baseline mixed-meal tolerance test (MMTT) at Visit 1. Individuals with diabetes or prediabetes determined through a previous HbA1c ≥ 5.7% or fingerstick glucose levels during the MMTT (fasting glucose of ≥100 mg/dL, 1-hour glucose ≥155 mg/dL, or 2-hour glucose >=140 mg/dL. will be invited to participate in the acute orforglipron challenge and another MMTT at Visit 2.

Participants eligible for the orforglipron challenge will receive orforglipron 2.5mg daily for 13 days at home leading up to Visit 2, another MMTT, during which participants will take the final (14th) dose of orforglipron 2.5mg 30 minutes before starting another MMTT.

03

Conditions studied

  • Diabete Type 2
  • Pharmacogenomic Drug Interaction
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or non-pregnant female volunteers (Age 18-79)
  • Not currently taking more than two home oral antidiabetic agents, with or without a diagnosis of type 2 diabetes
  • Able and willing to stop home oral antidiabetic medications for 5 days prior to the start of the study, with approval from healthcare providers
  • Able and willing to give

Exclusion criteria

Exclusion Criteria:

  • Known for orforglipron (e.g., Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN 2), allergies to any component)
  • Personal history of pancreatitis, gallbladder disease, intestinal malabsorption, severe gastroparesis, gastric outlet obstruction, or other gastrointestinal motility disorder
  • History of liver disease or (AST) or alanine aminotransferase (ALT) >3 x
  • Estimated (eGFR) \< 45 mg/min/1.73m2 per the Modification of Diet in Renal Disease equation
  • Active gallbladder disease or cholecystectomy within the past 6 months
  • Current use of a strong inducer (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, rifabutin, or St. John's wort) or ritonavir, cobicistat, cyclosporine, or another strong CYP3A4 inhibitor that also inhibits OATP1B
  • Current simvastatin dose >20 mg daily
  • Measured most recent level greater than 7.5% in the last 6 months
  • Average glucose by fingerstick or continuous glucose monitor exceeding 180 mg/dL in the last 3 months
  • Current uses of any oral or injectable GLP-1 receptor agonists, insulin, or the use of two or more antidiabetic agents
  • Currently taking or planning to start other medication known to affect glycemic parameters, such as , growth hormone, or fluoroquinolones during the study
  • Planned to change any prescribed medication during the study
  • Planned surgeries or procedures requiring general anesthesia during or within 10 days after completing the study
  • Participating in any other interventional study simultaneously
  • Dietary restrictions that prevent the consumption of the standardized liquid mixed meal
  • Pregnant, nursing, or postpartum in the last 6 months
  • Current suicidal ideation or suicide attempt within the past 5 years
  • Psychiatric illness, substance use disorder, or eating disorder that, in the opinion of the investigator, would compromise participant safety or study compliance
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Drug challenge

    MMTT after 12 doses of orforglipron 2.5 mg

    Drug: Orforglipron

  • No intervention
    Baseline

    MMTT pre-drug challenge

Interventions

06

What researchers measure

Primary outcomes

  1. Physiologic characterization by MMTT

    The primary endpoint will be glucose area under the curve (AUCglc) over the timeframe. For β-cell function, we will assess the first phase of insulin secretion with the insulinogenic index. For insulin resistance, we will calculate HOMA-IR and Matsuda index of insulin sensitivity. We will also capture both phases of insulin secretion by calculating the insulin AUC (AUCins) divided by the AUCglc.

    Time frame: 1 day

  2. The acute drug challenges

    The primary endpoint will be the difference in AUCglc over 180 minutes with drug administration vs. the MMTT without drug administration in Visit 1. We selected this endpoint because the decreased in post-prandial glucose is the most clinically relevant measure of drug response116. Secondary endpoints will include the difference between AUCins/AUCglc, the insulinogenic index (first phase of insulin secretion), and the Matsuda insulin sensitivity.

    Time frame: 12 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2029, 35 months later.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 35 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2030
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07739537
Responsible party
Aaron Leong (Clinician Investigator, Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Jul 31, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

Nopporn Thangthaeng, PhD, DNP
Contact
pathst2d@mgb.org
617-726-8767

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion